After taking a hit last week on news of an anticipated delay with cancer drug satraplatin, shares of Pharmion Corp. gained back ground - and then some - after reporting Phase III data showing that Vidaza, its myelodysplastic syndromes drug, extended overall survival by 74 percent in higher-risk MDS patients. (BioWorld Today)

After taking a hit last week on news of an anticipated delay with cancer drug satraplatin, shares of Pharmion Corp. gained back ground - and then some - after reporting Phase III data showing that Vidaza, its myelodysplastic syndromes drug, extended overall survival by 74 percent in higher-risk MDS patients. (BioWorld Today)